Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus

Rosa Maria Diaz, Feorillo Galivo, Timothy Kottke, Phonphimon Wongthida, Jian Qiao, Jill Thompson, Mikael Valdes, Glen Barber, Richard G. Vile

Research output: Contribution to journalArticle

193 Citations (Scopus)

Abstract

Relatively little attention has been paid to the role of virotherapy in promoting antitumor immune responses. Here, we show that CD8+ T cells are critical for the efficacy of intratumoral vesicular stomatitis virus virotherapy and are induced against both virally encoded and tumor-associated immunodominant epitopes. We tested three separate immune interventions to increase the frequency/activity of activated antitumoral T cells. Depletion of Treg had a negative therapeutic effect because it relieved suppression of the antiviral immune response, leading to early viral clearance. In contrast, increasing the circulating levels of tumor antigen-specific T cells using adoptive T cell transfer therapy, in combination with intratumoral virotherapy, generated significantly improved therapy over either adoptive therapy or virotherapy alone. Moreover, the incorporation of a tumor-associated antigen within the oncolytic vesicular stomatitis virus increased the levels of activation of naive T cells against the antigen, which translated into increased antitumor therapy. Therefore, our results show that strategies which enhance immune activation against tumor-associated antigens can also be used to enhance the efficacy of virotherapy.

Original languageEnglish (US)
Pages (from-to)2840-2848
Number of pages9
JournalCancer Research
Volume67
Issue number6
DOIs
StatePublished - Mar 15 2007

Fingerprint

Vesicular Stomatitis
Melanoma
Viruses
T-Lymphocytes
Neoplasm Antigens
Immunodominant Epitopes
Adoptive Transfer
Therapeutic Uses
Cell- and Tissue-Based Therapy
Antiviral Agents
Therapeutics
Antigens
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Diaz, R. M., Galivo, F., Kottke, T., Wongthida, P., Qiao, J., Thompson, J., ... Vile, R. G. (2007). Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Research, 67(6), 2840-2848. https://doi.org/10.1158/0008-5472.CAN-06-3974

Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. / Diaz, Rosa Maria; Galivo, Feorillo; Kottke, Timothy; Wongthida, Phonphimon; Qiao, Jian; Thompson, Jill; Valdes, Mikael; Barber, Glen; Vile, Richard G.

In: Cancer Research, Vol. 67, No. 6, 15.03.2007, p. 2840-2848.

Research output: Contribution to journalArticle

Diaz, RM, Galivo, F, Kottke, T, Wongthida, P, Qiao, J, Thompson, J, Valdes, M, Barber, G & Vile, RG 2007, 'Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus', Cancer Research, vol. 67, no. 6, pp. 2840-2848. https://doi.org/10.1158/0008-5472.CAN-06-3974
Diaz, Rosa Maria ; Galivo, Feorillo ; Kottke, Timothy ; Wongthida, Phonphimon ; Qiao, Jian ; Thompson, Jill ; Valdes, Mikael ; Barber, Glen ; Vile, Richard G. / Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. In: Cancer Research. 2007 ; Vol. 67, No. 6. pp. 2840-2848.
@article{b96affdae1254d27b064659c80dc9168,
title = "Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus",
abstract = "Relatively little attention has been paid to the role of virotherapy in promoting antitumor immune responses. Here, we show that CD8+ T cells are critical for the efficacy of intratumoral vesicular stomatitis virus virotherapy and are induced against both virally encoded and tumor-associated immunodominant epitopes. We tested three separate immune interventions to increase the frequency/activity of activated antitumoral T cells. Depletion of Treg had a negative therapeutic effect because it relieved suppression of the antiviral immune response, leading to early viral clearance. In contrast, increasing the circulating levels of tumor antigen-specific T cells using adoptive T cell transfer therapy, in combination with intratumoral virotherapy, generated significantly improved therapy over either adoptive therapy or virotherapy alone. Moreover, the incorporation of a tumor-associated antigen within the oncolytic vesicular stomatitis virus increased the levels of activation of naive T cells against the antigen, which translated into increased antitumor therapy. Therefore, our results show that strategies which enhance immune activation against tumor-associated antigens can also be used to enhance the efficacy of virotherapy.",
author = "Diaz, {Rosa Maria} and Feorillo Galivo and Timothy Kottke and Phonphimon Wongthida and Jian Qiao and Jill Thompson and Mikael Valdes and Glen Barber and Vile, {Richard G.}",
year = "2007",
month = "3",
day = "15",
doi = "10.1158/0008-5472.CAN-06-3974",
language = "English (US)",
volume = "67",
pages = "2840--2848",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus

AU - Diaz, Rosa Maria

AU - Galivo, Feorillo

AU - Kottke, Timothy

AU - Wongthida, Phonphimon

AU - Qiao, Jian

AU - Thompson, Jill

AU - Valdes, Mikael

AU - Barber, Glen

AU - Vile, Richard G.

PY - 2007/3/15

Y1 - 2007/3/15

N2 - Relatively little attention has been paid to the role of virotherapy in promoting antitumor immune responses. Here, we show that CD8+ T cells are critical for the efficacy of intratumoral vesicular stomatitis virus virotherapy and are induced against both virally encoded and tumor-associated immunodominant epitopes. We tested three separate immune interventions to increase the frequency/activity of activated antitumoral T cells. Depletion of Treg had a negative therapeutic effect because it relieved suppression of the antiviral immune response, leading to early viral clearance. In contrast, increasing the circulating levels of tumor antigen-specific T cells using adoptive T cell transfer therapy, in combination with intratumoral virotherapy, generated significantly improved therapy over either adoptive therapy or virotherapy alone. Moreover, the incorporation of a tumor-associated antigen within the oncolytic vesicular stomatitis virus increased the levels of activation of naive T cells against the antigen, which translated into increased antitumor therapy. Therefore, our results show that strategies which enhance immune activation against tumor-associated antigens can also be used to enhance the efficacy of virotherapy.

AB - Relatively little attention has been paid to the role of virotherapy in promoting antitumor immune responses. Here, we show that CD8+ T cells are critical for the efficacy of intratumoral vesicular stomatitis virus virotherapy and are induced against both virally encoded and tumor-associated immunodominant epitopes. We tested three separate immune interventions to increase the frequency/activity of activated antitumoral T cells. Depletion of Treg had a negative therapeutic effect because it relieved suppression of the antiviral immune response, leading to early viral clearance. In contrast, increasing the circulating levels of tumor antigen-specific T cells using adoptive T cell transfer therapy, in combination with intratumoral virotherapy, generated significantly improved therapy over either adoptive therapy or virotherapy alone. Moreover, the incorporation of a tumor-associated antigen within the oncolytic vesicular stomatitis virus increased the levels of activation of naive T cells against the antigen, which translated into increased antitumor therapy. Therefore, our results show that strategies which enhance immune activation against tumor-associated antigens can also be used to enhance the efficacy of virotherapy.

UR - http://www.scopus.com/inward/record.url?scp=34047262198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047262198&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-3974

DO - 10.1158/0008-5472.CAN-06-3974

M3 - Article

C2 - 17363607

AN - SCOPUS:34047262198

VL - 67

SP - 2840

EP - 2848

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 6

ER -